Trial Title:
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
NCT ID:
NCT05638295
Condition:
Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Conditions: Official terms:
Neoplasms
Antineoplastic Agents, Immunological
Panitumumab
Sotorasib
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Biopsy
Description:
Undergo tumor biopsy
Arm group label:
Cohort I Arm A (sotorasib, panitumumab)
Arm group label:
Cohort I Arm B (sotorasib)
Arm group label:
Cohort II (sotorasib, panitumumab)
Other name:
BIOPSY_TYPE
Other name:
Bx
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood
Arm group label:
Cohort I Arm A (sotorasib, panitumumab)
Arm group label:
Cohort I Arm B (sotorasib)
Arm group label:
Cohort II (sotorasib, panitumumab)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT scan
Arm group label:
Cohort I Arm A (sotorasib, panitumumab)
Arm group label:
Cohort I Arm B (sotorasib)
Arm group label:
Cohort II (sotorasib, panitumumab)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Cohort I Arm A (sotorasib, panitumumab)
Arm group label:
Cohort I Arm B (sotorasib)
Arm group label:
Cohort II (sotorasib, panitumumab)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Biological
Intervention name:
Panitumumab
Description:
Given IV
Arm group label:
Cohort I Arm A (sotorasib, panitumumab)
Arm group label:
Cohort II (sotorasib, panitumumab)
Other name:
ABX-EGF
Other name:
ABX-EGF Monoclonal Antibody
Other name:
ABX-EGF, Clone E7.6.3
Other name:
E7.6.3
Other name:
Human IgG2K Monoclonal Antibody
Other name:
MoAb ABX-EGF
Other name:
MoAb E7.6.3
Other name:
Monoclonal Antibody ABX-EGF
Other name:
Monoclonal Antibody E7.6.3
Other name:
Vectibix
Intervention type:
Drug
Intervention name:
Sotorasib
Description:
Given PO
Arm group label:
Cohort I Arm A (sotorasib, panitumumab)
Arm group label:
Cohort I Arm B (sotorasib)
Arm group label:
Cohort II (sotorasib, panitumumab)
Other name:
AMG 510
Other name:
AMG-510
Other name:
AMG510
Other name:
Lumakras
Other name:
Lumykras
Summary:
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or
without panitumumab works in treating patients with KRAS G12C mutant solid tumors that
may have spread from where it first started to nearby tissue, lymph nodes, or distant
parts of the body (advanced). Sotorasib is in a class of medications called KRAS
inhibitors. It works by blocking the action of the abnormal protein that signals cancer
cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in
a class of medications called monoclonal antibodies. It works by slowing or stopping the
growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor
cells in patients with advanced solid tumors with KRAS G12C mutation.
Detailed description:
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as
compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C
mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma
[NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in
patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on
a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as
compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid
tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and
overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in
patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on
a prior KRAS G12C inhibitor as measured by disease control rate, progression free
survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510
(sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess
concordance between the diagnostic tumor mutation profile generated by the Designated
Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment
circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from
plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To
evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to
treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of
clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or
resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A
or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and
panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28
days in the absence of disease progression or unacceptable toxicity. Patients also
undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic
resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every
28 days in the absence of disease progression or unacceptable toxicity. Patients with
disease progression may cross-over to cohort II. Patients also undergo collection of
blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every
3-6 months for up to 36 months.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient must have enrolled onto EAY191 and must have been given a treatment
assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable
mutation as defined in EAY191
- Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the
time of registration/randomization to the EAY191-E5 study
- Patient must be >= 18 years of age
- Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening
assessment
- Patient must have disease that can be safely biopsied and agree to a pre-treatment
biopsy or have tissue available from within 12 months prior to the date of
registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration
list for this treatment trial can be found on the Cancer Trials Support Unit
(CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described
in the ComboMATCH registration protocol
- Patient must have cytologically/histologically confirmed advanced/metastatic solid
tumor
- Patient must have progressed on at least one line of standard of care therapy in the
advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor
receptor (EGFR) inhibitor will meet this criterion
- Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of
=< 2 (or Karnofsky performance status >= 60%)
- Patient must have at least one measurable lesion as defined by Response Evaluation
Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days
prior to registration/randomization
- Patient must not have any serious active infection within 4 weeks prior to EAY191-E5
registration/randomization (e.g., requiring hospitalization and/or intravenous [IV]
antibiotics) or currently receiving oral or IV antibiotics for the treatment of
infection. Patients receiving prophylactic antibiotics are eligible
- Patient must have the ability to retain oral medication and not have any clinically
significant gastrointestinal abnormalities that might alter absorption
- Patient must not have any history of or current evidence of non-infectious
interstitial lung disease (ILD)/pneumonitis
- Patient must not have a history of allergic reactions attributed to either of the
study agents or to agents of similar chemical or biologic composition
- Patient must have completed full treatment cycle 21 days prior to EAY191-E5
registration/randomization if they have received prior chemotherapy, biological
cancer therapy, radiation therapy or an investigational agent/device. Patients must
have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or
better from any adverse events due to prior cancer therapy (with the exception of
alopecia)
- Patient must not be pregnant or breast-feeding due to the potential harm to an
unborn fetus and possible risk for adverse events in nursing infants with the
treatment regimens being used. All patients of childbearing potential must have a
blood test or urine study within 14 days prior to registration/randomization to rule
out pregnancy. A patient of childbearing potential is defined as anyone, regardless
of sexual orientation or whether they have undergone tubal ligation, who meets the
following criteria: 1) has achieved menarche at some point, 2) has not undergone a
hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal
(amenorrhea following cancer therapy does not rule out childbearing potential) for
at least 24 consecutive months (i.e., has had menses at any time in the preceding 24
consecutive months)
- Patient must not expect to conceive or father children by using accepted and
effective method(s) of contraception or by abstaining from sexual intercourse for
the duration of their participation in the study and for at least 6 months after the
last dose of protocol treatment. Patients must not breastfeed while receiving
protocol treatment and for one week (7 days) after the last dose of AMG 510
(sotorasib) and 2 months after the last dose of panitumumab
- Patients must not have neuropathy ≥ grade 2 within 14 days prior to
registration/randomization
- Patients with treated brain metastases are eligible if follow-up brain imaging after
central nervous system (CNS)-directed therapy shows no evidence of progression
- Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral
therapy with undetectable viral load within 6 months are eligible for this trial
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment of
the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac history, or history of
treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
function using the New York Heart Association Functional Classification. To be
eligible for this trail, patients should be class 2B or better
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28
days prior to protocol registration/randomization)
- Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT])
< 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol
registration/randomization)
- Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2
for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤
28 days prior to protocol registration/randomization)
- COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
- COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
- COHORT II: Patient must have progressed after treatment at the recommended phase II
dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510
[sotorasib] alone) may be eligible to enroll on cohort 2 and receive
combination treatment with panitumumab and AMG 510 (sotorasib). Patients must
meet performance status requirements and laboratory values as above and must be
begin treatment within 7 days of enrollment. Migration to cohort 2 must take
place within 6 months of progression, with no intervening anti-cancer therapy
given.
- NOTE: Cohort migration following disease progression is dependent on a slot
being available. MATCHBox makes the new treatment assignment following
initiation of a step 2 registration for this treatment trial
- COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor
in combination with an EGFR inhibitor
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Alabama at Birmingham Cancer Center
Address:
City:
Birmingham
Zip:
35233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
205-934-0220
Email:
tmyrick@uab.edu
Investigator:
Last name:
Rebecca C. Arend
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Florida
Address:
City:
Jacksonville
Zip:
32224-9980
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Aaron S. Mansfield
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Boise
Address:
City:
Boise
Zip:
83706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Boise
Address:
City:
Boise
Zip:
83712
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Caldwell
Address:
City:
Caldwell
Zip:
83605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Fruitland
Address:
City:
Fruitland
Zip:
83619
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Meridian
Address:
City:
Meridian
Zip:
83642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Luke's Cancer Institute - Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
208-381-2774
Email:
eslinget@slhs.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Advocate Good Shepherd Hospital
Address:
City:
Barrington
Zip:
60010
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-842-4847
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
John H Stroger Jr Hospital of Cook County
Address:
City:
Chicago
Zip:
60612
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-864-5204
Investigator:
Last name:
Thomas E. Lad
Email:
Principal Investigator
Facility:
Name:
Advocate Illinois Masonic Medical Center
Address:
City:
Chicago
Zip:
60657
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-296-5360
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
AMG Crystal Lake - Oncology
Address:
City:
Crystal Lake
Zip:
60014
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocate.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Kendrith M. Rowland
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Advocate Good Samaritan Hospital
Address:
City:
Downers Grove
Zip:
60515
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-275-1270
Email:
Barbara.barhamand@advocatehealth.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Kendrith M. Rowland
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Advocate Sherman Hospital
Address:
City:
Elgin
Zip:
60123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-429-2907
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Advocate South Suburban Hospital
Address:
City:
Hazel Crest
Zip:
60429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
708-799-9995
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
AMG Libertyville - Oncology
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Condell Memorial Hospital
Address:
City:
Libertyville
Zip:
60048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-929-6129
Email:
advocateresearch@advocatehealth.com
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Kendrith M. Rowland
Email:
Principal Investigator
Facility:
Name:
Loyola University Medical Center
Address:
City:
Maywood
Zip:
60153
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
708-226-4357
Investigator:
Last name:
Kathleen Kennedy
Email:
Principal Investigator
Facility:
Name:
Advocate Christ Medical Center
Address:
City:
Oak Lawn
Zip:
60453-2699
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-323-8622
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Advocate Outpatient Center - Oak Lawn
Address:
City:
Oak Lawn
Zip:
60453
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ncorp@aah.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Advocate High Tech Medical Park
Address:
City:
Palos Heights
Zip:
60463
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ncorp@aah.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Advocate Lutheran General Hospital
Address:
City:
Park Ridge
Zip:
60068
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
847-384-3621
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital East
Address:
City:
Shiloh
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-747-9912
Email:
dschwab@wustl.edu
Investigator:
Last name:
Kian-Huat Lim
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Memorial Hospital
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Kendrith M. Rowland
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Ankeny
Address:
City:
Ankeny
Zip:
50023
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-282-2921
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Des Moines
Address:
City:
Des Moines
Zip:
50309
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Seema Harichand-Herdt
Email:
Principal Investigator
Facility:
Name:
University of Kentucky/Markey Cancer Center
Address:
City:
Lexington
Zip:
40536
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
859-257-3379
Investigator:
Last name:
Susanne M. Arnold
Email:
Principal Investigator
Facility:
Name:
Lafayette Family Cancer Center-EMMC
Address:
City:
Brewer
Zip:
04412
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-987-3005
Investigator:
Last name:
Sarah J. Sinclair
Email:
Principal Investigator
Facility:
Name:
University of Maryland/Greenebaum Cancer Center
Address:
City:
Baltimore
Zip:
21201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-888-8823
Investigator:
Last name:
Ranee Mehra
Email:
Principal Investigator
Facility:
Name:
National Institutes of Health Clinical Center
Address:
City:
Bethesda
Zip:
20892
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-411-1222
Investigator:
Last name:
Jibran Ahmed
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Dearborn Hospital
Address:
City:
Dearborn
Zip:
48124
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Corewell Health Farmington Hills Hospital
Address:
City:
Farmington Hills
Zip:
48336
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
University of Michigan Health - Sparrow Lansing
Address:
City:
Lansing
Zip:
48912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
517-364-3712
Email:
harsha.trivedi@umhsparrow.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Children's
Address:
City:
Royal Oak
Zip:
48073
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Corewell Health William Beaumont University Hospital
Address:
City:
Royal Oak
Zip:
48073
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Saginaw
Address:
City:
Saginaw
Zip:
48601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Oncology Hematology Associates of Saginaw Valley PC
Address:
City:
Saginaw
Zip:
48604
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Tawas
Address:
City:
Tawas City
Zip:
48764
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Corewell Health Beaumont Troy Hospital
Address:
City:
Troy
Zip:
48085
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-551-7695
Investigator:
Last name:
Dana Zakalik
Email:
Principal Investigator
Facility:
Name:
Saint Mary's Oncology/Hematology Associates of West Branch
Address:
City:
West Branch
Zip:
48661
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Huron Gastroenterology PC
Address:
City:
Ypsilanti
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Essentia Health - Deer River Clinic
Address:
City:
Deer River
Zip:
56636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Cancer Center
Address:
City:
Duluth
Zip:
55805
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Hibbing Clinic
Address:
City:
Hibbing
Zip:
55746
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Mayo Clinic in Rochester
Address:
City:
Rochester
Zip:
55905
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-776-0015
Investigator:
Last name:
Aaron S. Mansfield
Email:
Principal Investigator
Facility:
Name:
Essentia Health Sandstone
Address:
City:
Sandstone
Zip:
55072
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Virginia Clinic
Address:
City:
Virginia
Zip:
55792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Saint Francis Medical Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
573-334-2230
Email:
sfmc@sfmc.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at West County Hospital
Address:
City:
Creve Coeur
Zip:
63141
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Kian-Huat Lim
Email:
Principal Investigator
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Kian-Huat Lim
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center-South County
Address:
City:
Saint Louis
Zip:
63129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Kian-Huat Lim
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Christian Hospital
Address:
City:
Saint Louis
Zip:
63136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Kian-Huat Lim
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Saint Peters Hospital
Address:
City:
Saint Peters
Zip:
63376
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Kian-Huat Lim
Email:
Principal Investigator
Facility:
Name:
Community Hospital of Anaconda
Address:
City:
Anaconda
Zip:
59711
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Logan Health Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
Alan K. Ikeda
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
Alan K. Ikeda
Email:
Principal Investigator
Facility:
Name:
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Address:
City:
Las Vegas
Zip:
89135
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
Alan K. Ikeda
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
Alan K. Ikeda
Email:
Principal Investigator
Facility:
Name:
Rutgers Cancer Institute of New Jersey
Address:
City:
New Brunswick
Zip:
08903
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-235-7356
Investigator:
Last name:
Patrick M. Boland
Email:
Principal Investigator
Facility:
Name:
University of New Mexico Cancer Center
Address:
City:
Albuquerque
Zip:
87106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
505-925-0348
Email:
HSC-ClinicalTrialInfo@salud.unm.edu
Investigator:
Last name:
Ursa A. Brown-Glaberman
Email:
Principal Investigator
Facility:
Name:
Roswell Park Cancer Institute
Address:
City:
Buffalo
Zip:
14263
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-767-9355
Email:
askroswell@roswellpark.org
Investigator:
Last name:
Ellis G. Levine
Email:
Principal Investigator
Facility:
Name:
NYU Langone Hospital - Long Island
Address:
City:
Mineola
Zip:
11501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-263-4432
Email:
cancertrials@nyulangone.org
Investigator:
Last name:
Kristen R. Spencer
Email:
Principal Investigator
Facility:
Name:
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Address:
City:
New York
Zip:
10016
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
CancerTrials@nyulangone.org
Investigator:
Last name:
Kristen R. Spencer
Email:
Principal Investigator
Facility:
Name:
Columbus Oncology and Hematology Associates Inc
Address:
City:
Columbus
Zip:
43214
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Riverside Methodist Hospital
Address:
City:
Columbus
Zip:
43214
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Grant Medical Center
Address:
City:
Columbus
Zip:
43215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Doctors Hospital
Address:
City:
Columbus
Zip:
43228
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Dayton Physician LLC - Englewood
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Delaware Health Center-Grady Cancer Center
Address:
City:
Delaware
Zip:
43015
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Grady Memorial Hospital
Address:
City:
Delaware
Zip:
43015
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Columbus Oncology and Hematology Associates
Address:
City:
Dublin
Zip:
43016
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Dublin Methodist Hospital
Address:
City:
Dublin
Zip:
43016
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
Kettering Medical Center
Address:
City:
Kettering
Zip:
45429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
OhioHealth Mansfield Hospital
Address:
City:
Mansfield
Zip:
44903
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
OhioHealth Marion General Hospital
Address:
City:
Marion
Zip:
43302
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
614-788-3860
Email:
Jennifer.Sexton@ohiohealth.com
Investigator:
Last name:
Sanjay Yadav
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Raid Aljumaily
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Ontario
Address:
City:
Ontario
Zip:
97914
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
ECOG-ACRIN Cancer Research Group
Address:
City:
Philadelphia
Zip:
19103
Country:
United States
Status:
Recruiting
Contact:
Last name:
Kristen R. Spencer
Phone:
212-731-6667
Email:
Kristen.Spencer@nyulangone.org
Investigator:
Last name:
Kristen R. Spencer
Email:
Principal Investigator
Facility:
Name:
Thomas Jefferson University Hospital
Address:
City:
Philadelphia
Zip:
19107
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Steven J. Cohen
Email:
Principal Investigator
Facility:
Name:
Asplundh Cancer Pavilion
Address:
City:
Willow Grove
Zip:
19090
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Steven J. Cohen
Email:
Principal Investigator
Facility:
Name:
University of Virginia Cancer Center
Address:
City:
Charlottesville
Zip:
22908
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
434-243-6303
Email:
uvacancertrials@hscmail.mcc.virginia.edu
Investigator:
Last name:
Matthew J. Reilley
Email:
Principal Investigator
Facility:
Name:
Swedish Medical Center-First Hill
Address:
City:
Seattle
Zip:
98122
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
206-215-3086
Email:
PCRC-NCORP@Swedish.org
Investigator:
Last name:
Alison K. Conlin
Email:
Principal Investigator
Facility:
Name:
Duluth Clinic Ashland
Address:
City:
Ashland
Zip:
54806
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Southern Lakes VLCC
Address:
City:
Burlington
Zip:
53105
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's South Shore
Address:
City:
Cudahy
Zip:
53110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Health Care Germantown Health Center
Address:
City:
Germantown
Zip:
53022
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Grafton
Address:
City:
Grafton
Zip:
53024
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora BayCare Medical Center
Address:
City:
Green Bay
Zip:
54311
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Kenosha South
Address:
City:
Kenosha
Zip:
53142
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Gundersen Lutheran Medical Center
Address:
City:
La Crosse
Zip:
54601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
608-775-2385
Email:
cancerctr@gundersenhealth.org
Investigator:
Last name:
Kurt Oettel
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Address:
City:
Madison
Zip:
53718
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Dustin A. Deming
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - University Hospital
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Dustin A. Deming
Email:
Principal Investigator
Facility:
Name:
Aurora Bay Area Medical Group-Marinette
Address:
City:
Marinette
Zip:
54143
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee
Address:
City:
Milwaukee
Zip:
53209
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Saint Luke's Medical Center
Address:
City:
Milwaukee
Zip:
53215
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Sinai Medical Center
Address:
City:
Milwaukee
Zip:
53233
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic - Oshkosh
Address:
City:
Oshkosh
Zip:
54904
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Racine
Address:
City:
Racine
Zip:
53406
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Medical Center in Summit
Address:
City:
Summit
Zip:
53066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Vince Lombardi Cancer Clinic-Two Rivers
Address:
City:
Two Rivers
Zip:
54241
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora Cancer Care-Milwaukee West
Address:
City:
Wauwatosa
Zip:
53226
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Facility:
Name:
Aurora West Allis Medical Center
Address:
City:
West Allis
Zip:
53227
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-302-2304
Email:
ncorp@aurora.org
Investigator:
Last name:
Thomas J. Saphner
Email:
Principal Investigator
Start date:
August 1, 2024
Completion date:
December 31, 2025
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05638295
